2cureX AB (publ)

Symbol: 2CUREX.ST




Market price today

  • -0.9376

    P/E Ratio

  • 0.0026

    PEG Ratio

  • 28.43M

    MRK Cap

  • 0.00%

    DIV Yield

2cureX AB (publ) (2CUREX-ST) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Kenneth Graabek Johansen
Full-time employees:14
Address:Fruebjergvej 3

2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also conducting various clinical programs for IndiTreat for breast colorectal, ovarian, and pancreatic cancers. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.

General Outlook

In simple terms, 2cureX AB (publ) has 17.603 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep -171.401% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -211.299%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -179.317%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -1.801% return, is a testament to 2cureX AB (publ)'s adeptness in optimizing resource deployment. 2cureX AB (publ)'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.268%. Furthermore, the proficiency of 2cureX AB (publ) in capital utilization is underscored by a remarkable -2.578% return on capital employed.

Stock Prices

2cureX AB (publ)'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.65, while its low point bottomed out at $1.49. This variance in figures offers investors a lucid insight into the roller-coaster ride that is 2cureX AB (publ)'s stock market.

Liquidity Ratios

Analyzing 2CUREX.ST liquidity ratios reveals its financial health of the firm. The current ratio of 542.49% gauges short-term asset coverage for liabilities. The quick ratio (542.49%) assesses immediate liquidity, while the cash ratio (456.66%) indicates cash reserves.

Current Ratio542.49%
Quick Ratio542.49%
Cash Ratio456.66%

Profitability Ratios

2CUREX.ST profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -21226.35% underscores its earnings before tax deductions. The effective tax rate stands at 15.52%, revealing its tax efficiency. The net income per EBT, 84.48%, and the EBT per EBIT, 100.46%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -21129.94%, we grasp its operational profitability.

Pretax Profit Margin-21226.35%
Effective Tax Rate15.52%
Net Income per EBT84.48%
EBT per EBIT100.46%
EBIT per Revenue-21129.94%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 5.42, it details the span from stock purchase to revenue. The 5 days it takes to settle debts showcases its creditor relations. Meanwhile, a 5 cash conversion cycle and 6.63% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding542
Operating Cycle5505.60
Cash Conversion Cycle5506
Receivables Turnover0.07
Fixed Asset Turnover0.24
Asset Turnover0.01

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.84, and free cash flow per share, -1.84, depict cash generation on a per-share basis. The cash per share value, 0.76, showcases liquidity position. Lastly, the operating cash flow sales ratio, -194.29, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-1.84
Free Cash Flow per Share-1.84
Cash per Share0.76
Operating Cash Flow Sales Ratio-194.29
Free Cash Flow to Operating Cash Flow Ratio1.00

Debt and Leverage Ratios

An interest coverage of 40.47 indicates its ability to manage interest expenses.

Interest Coverage40.47
Company Equity Multiplier1.21

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.01, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.75, reflects the portion of profit attributed to each share. The book value per share, 0.78, represents the net asset value distributed per share, while the tangible book value per share, 0.78, excludes intangible assets.

Revenue Per Share0.01
Net Income Per Share-1.75
Book Value Per Share0.78
Tangible Book Value Per Share0.78
Shareholders Equity Per Share0.78

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 72.22%, indicates top-line expansion, while the gross profit growth, -5.86%, reveals profitability trends. EBIT growth, -16.66%, and operating income growth, -16.66%, offer insights into operational profitability progression. The net income growth, -12.45%, showcases bottom-line expansion, and the EPS growth, -12.18%, measures the growth in earnings per share.

Revenue Growth72.22%
Gross Profit Growth-5.86%
EBIT Growth-16.66%
Operating Income Growth-16.66%
Net Income Growth-12.45%
EPS Growth-12.18%
EPS Diluted Growth-12.18%
Weighted Average Shares Growth0.12%
Weighted Average Shares Diluted Growth0.12%
Operating Cash Flow Growth-15.95%
Free Cash Flow Growth-13.75%
10-Year Revenue Growth per Share-96.66%
3-Year Revenue Growth per Share-99.22%
10-Year Operating CF Growth per Share-660.95%
5-Year Operating CF Growth per Share-1758.95%
3-Year Operating CF Growth per Share-114.45%
10-Year Net Income Growth per Share-2993.85%
5-Year Net Income Growth per Share-149.46%
3-Year Net Income Growth per Share-225.40%
10-Year Shareholders Equity Growth per Share-19.59%
5-Year Shareholders Equity Growth per Share-40.91%
3-Year Shareholders Equity Growth per Share-82.03%
Receivables Growth111.33%
Asset Growth-65.12%
Book Value per Share Growth-68.23%
SGA Expenses Growth-100.00%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 21,978,861.16, captures the company's total value, considering both debt and equity. Income quality, 1.05, assesses the reliability of reported earnings.

Enterprise Value21,978,861.16
Income Quality1.05
Graham Number5.54
Return on Tangible Assets-185.38%
Graham Net Net0.70
Working Capital12,987,000
Tangible Asset Value13,690,000
Net Current Asset Value12,987,000
Average Receivables1,855,500
Average Payables814,500
Days Sales Outstanding5932

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.05, and the price to book ratio, 2.05, reflect the market's valuation relative to the company's book value. The price to sales ratio, 168.12, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -0.87, and price to operating cash flows, -0.87, gauge market valuation against cash flow metrics.

Price Book Value Ratio2.05
Price to Book Ratio2.05
Price to Sales Ratio168.12
Price Cash Flow Ratio-0.87
Enterprise Value Multiple-1.19
Price Fair Value2.05
Price to Operating Cash Flow Ratio-0.87
Price to Free Cash Flows Ratio-0.87
Price to Tangible Book Ratio2.58
Enterprise Value to Sales141.80
Enterprise Value Over EBITDA-0.59
EV to Operating Cash Flow-0.68
Earnings Yield-87.10%
Free Cash Flow Yield-91.71%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of 2cureX AB (publ) (2CUREX.ST) on the STO in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.938 in 2024.

What is the ticker symbol of 2cureX AB (publ) stock?

The ticker symbol of 2cureX AB (publ) stock is 2CUREX.ST.

What is company IPO date?

IPO date of 2cureX AB (publ) is 2017-11-24.

What is company current share price?

Current share price is 1.615 SEK.

What is stock market cap today?

The market cap of stock today is 28428684.000.

What is PEG ratio in 2024?

The current 0.003 is 0.003 in 2024.

What is the number of employees in 2024?

In 2024 the company has 14.